2022 annual financial data
CytomX Therapeutics 2022 Net margin
CytomX Therapeutics 2022 net margin with verified reported values.
Direct answer
Net margin was -183.02%.
Operating income was -101,335,000 USD and net income was -97,299,000 USD.
Operating cash flow was -110,788,000 USD.
Get free CytomX Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 53,163,000 USD
- Operating income
- -101,335,000 USD
- Net income
- -97,299,000 USD
- Operating cash flow
- -110,788,000 USD